The Business of Fashion
Agenda-setting intelligence, analysis and advice for the global fashion community.
Agenda-setting intelligence, analysis and advice for the global fashion community.
Eli Lilly & Co. cautioned against using its popular diabetes and obesity drugs for “cosmetic weight loss” as off-label use of the medications has skyrocketed and shortages ensued.
“Mounjaro and Zepbound are indicated for the treatment of serious diseases; they are not approved for – and should not be used for – cosmetic weight loss,” the company said in a statement Thursday morning.
Neither drug is approved for weight loss in people who don’t have a diagnosis of type 2 diabetes or obesity. Weight-loss drugs were popularised after social media influencers on TikTok and celebrities like Elon Musk touted rival Novo Nordisk A/S’s Ozempic and Wegovy, which have similar effects. The demand prompted supply troubles, which impacted the ability of people with diabetes to get their medications.
Lilly did not outline any additional steps it is taking to prevent off-label use. The company also said it was concerned about knock-off versions of its medicines that have not been approved by the US Food and Drug Administration, some of which have been found to contain impurities.
ADVERTISEMENT
By Madison Muller
Learn more:
How Ozempic Changed the Face of Beauty
Famed for speedy weight loss, the effects of the prescription-only drug are now shifting beauty standards.
Mature consumers have long been ignored by the beauty industry. Now a small but growing number of emerging brands are responding to the needs of those over the age of 45 in a bid to cash in on their $15 trillion spending power.
Guerlain really wants to win this game.
The battle for exclusive international beauty launches is intensifying as Nykaa, Tira and more set their eyes on expansion.
As in-person retail continues to recover, store owners and marketers are working hard to press the main advantage analogue shopping has over digital: its appeal to all the senses.